US Patent Issued to Memorial Shan-Ketering Cancer Center, Memorial Hospital for Cancer and Allied Diseases, Sloan-Kettering Institute for Cancer Research, Biosplice Therapeutics on June 23 for "Combination therapy with CLK/DYRK inhibitors and BCL2 inhibitors to treat leukemia" (New York, California Inventors)

ALEXANDRIA, Va., July 15 -- United States Patent no. 12,661,352, issued on June 23, was assigned to Memorial Shan-Ketering Cancer Center (New York), Memorial Hospital for Cancer and Allied Diseases (New York), Sloan-Kettering Institute for Cancer Research (New York) and Biosplice Therapeutics Inc. (San Diego).

"Combination therapy with CLK/DYRK inhibitors and BCL2 inhibitors to treat leukemia" was invented by Carine Bossard (San Diego) and Omar Abdel-Wahab (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK/DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the method...